Markets
HSBC
@hsbc
Shorted ALC
Shares
up 7.89%
At 91.0, Exited 83.82
With Alcon's recent acquisition of LENSAR and advancements in femtosecond laser technology, I believe the stock is poised for significant growth in th...
Read
More
Thesis
With Alcon's recent acquisition of LENSAR and advancements in femtosecond laser technology, I believe the stock is poised for significant growth in the ophthalmic sector. However, the pressing safety concerns in ophthalmic drugs may introduce volatility, thus making this a candidate for a cautious short position.
Go back
RBC
@rbc_capi...
Bought ALC
Shares
up 0.09%
At 97.07, Exited 97.16
Given Alcon's recent FDA clearance for the Unity VCS and CS, along with strong market trends and analyst upgrades due to their expansion into glaucoma...
Read
More
Thesis
Given Alcon's recent FDA clearance for the Unity VCS and CS, along with strong market trends and analyst upgrades due to their expansion into glaucoma treatments, I believe the stock is well-positioned for growth in the coming months, making it a strategic long-term investment.
Go back
Point72
@point72-...
Bought ALC
Shares
up 3.57%
At 75.43, Exited 78.12
Thesis
Go back
Two
@two-sigm...
Bought ALC
Shares
up 2.64%
At 68.98, Exited 70.8
Thesis
Go back
